■检查玻璃体内0.2-μg/天氟轻松酮植入物(FAi)治疗后节段(PS)非感染性葡萄膜炎(NIU)的长期疗效和安全性。
■三年,第三阶段,多中心,随机化,双面蒙面,控制,前瞻性研究(clinicaltrials.gov,NCT02746991)。
■总的来说,印度153例NIU-PS≥1眼(有或没有前葡萄膜炎)≥1年的患者,在过去12个月中需要眼部注射或全身治疗的葡萄膜炎复发≥2次。
■患者以2:1的比例随机分配用于基线FAi或假注射,并监测主要结果指标。
■葡萄膜炎复发的发生率和时间,使用辅助治疗,最佳矫正视力,中央凹厚度,并监测超过36个月的眼压(IOP)和白内障相关事件。
■总的来说,153名患者(FAi,n=101;假治疗,n=52)。与接受假手术治疗的患者相比,氟轻松植入物治疗的眼葡萄膜炎复发率显着降低(46.5%vs.75.0%,分别为;P=0.001)和更长的中位复发时间(1116.0[95%置信区间,847.00tonotevaluable]vs.190.5[95%置信区间,处理假手术的100.0-395.0天)。两组之间的系统性辅助治疗相似,但需要辅助注射的FAi治疗的眼睛较少(8.9%vs.治疗假手术的51.9%)。两组之间的视觉结果相似,在36个月时,假手术和FAi治疗的眼睛中,残余黄斑水肿更常见(46.2%vs.24.2%,分别)。从第12个月起,FAi治疗组的中央凹厚度较低。两组的眼内压降低手术均稳定,但是,正如预期的那样,FAi治疗组的IOP升高率高于治疗组(IOP>25mmHg:23.8%vs.3.8%;眼压>30mmHg:16.8%vs.1.9%,分别),和FAi治疗的眼睛白内障手术的发生率高于治疗的假手术(70.5%vs.26.5%,分别)。
■在患有NIU-PS的患者中,0.2-μg/天FAi与葡萄膜炎复发减少和首次复发时间增加相关,同时控制黄斑水肿,维持稳定的IOP水平,并提供预期的安全概况,包括36个月以上白内障形成的发生率较高。
■作者对本文讨论的任何材料都没有专有或商业利益。
UNASSIGNED: To examine the long-term efficacy and safety of the intravitreal 0.2-μg/day fluocinolone acetonide implant (FAi) to treat noninfectious uveitis (NIU) of the posterior segment (PS).
UNASSIGNED: Three-year, phase III, multicenter, randomized, double-masked, controlled, prospective study (clinicaltrials.gov, NCT02746991).
UNASSIGNED: Overall, 153 patients in India with NIU-PS in ≥ 1 eye (with or without anterior uveitis) for ≥ 1 year who had ≥ 2 separate recurrences of uveitis requiring ocular injections or systemic therapy in the prior 12 months.
UNASSIGNED: Patients were randomized 2:1 for baseline FAi or sham injection and monitored for main outcome measures.
UNASSIGNED: Incidence and timing of uveitis recurrence, use of adjunctive therapy, best-corrected visual acuity, central foveal thickness, and monitoring of intraocular pressure (IOP)- and cataract-related events over 36 months.
UNASSIGNED: Overall, 153 patients (FAi, n = 101; treated sham, n = 52) were enrolled. Fluocinolone acetonide implant-treated eyes had significantly reduced uveitis recurrence rates versus treated sham (46.5% vs. 75.0%, respectively; P = 0.001) and a longer median time to recurrence (1116.0 [95% confidence interval, 847.00 to not evaluable] vs. 190.5 [95% confidence interval, 100.0-395.0] days for treated sham). Systemic adjunctive treatments were similar between groups, but fewer FAi-treated eyes required adjunctive injections (8.9% vs. 51.9% for treated sham). Visual outcomes were similar between groups, and residual macular edema was more common at 36 months in treated sham versus FAi-treated eyes (46.2% vs. 24.2%, respectively). The FAi-treated group had a lower central foveal thickness from month 12 onward. Intraocular pressure-lowering surgeries were stable in both groups, but, as expected, rates of IOP elevations were more frequent in the FAi-treated group than in the treated sham (IOP > 25 mmHg: 23.8% vs. 3.8%; IOP > 30 mmHg: 16.8% vs. 1.9%, respectively), and FAi-treated eyes had a higher incidence of cataract surgery than the treated sham (70.5% vs. 26.5%, respectively).
UNASSIGNED: In patients with NIU-PS, the 0.2-μg/day FAi is associated with reduced-uveitis recurrence and increased time to first recurrence while controlling macular edema, maintaining stable IOP levels, and providing an expected safety profile, including a higher occurrence of cataract formation over 36 months.
UNASSIGNED: The authors have no proprietary or commercial interest in any materials discussed in this article.